2018
DOI: 10.1038/s41426-017-0015-8
|View full text |Cite
|
Sign up to set email alerts
|

Candida blankii : an emergent opportunistic yeast with reduced susceptibility to antifungals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
21
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 17 publications
(22 citation statements)
references
References 13 publications
1
21
0
Order By: Relevance
“…3 (A) and (B)). Although no approved susceptibility breakpoints for C. blankii are yet available, our susceptibility results to antifungal agents are comparable with a previous report [2] . Because the isolate showed reduced susceptibility to fluconazole by Etest (≥12 μg/mL) and VITEK 2 identified it as S .…”
Section: Resultssupporting
confidence: 89%
See 4 more Smart Citations
“…3 (A) and (B)). Although no approved susceptibility breakpoints for C. blankii are yet available, our susceptibility results to antifungal agents are comparable with a previous report [2] . Because the isolate showed reduced susceptibility to fluconazole by Etest (≥12 μg/mL) and VITEK 2 identified it as S .…”
Section: Resultssupporting
confidence: 89%
“…The isolate (Kw593/18) was unequivocally identified as C. blankii because the ITS region of rDNA (GenBank accession no. LT993736) exhibited 100% sequence identity with the corresponding sequence from type strain (CBS1898) as well as several other (CBS6427, CBS7205, CBS1989 and CBS6788) strains, and only one nucleotide difference with a bloodstream isolate (HCFMUSP01) of C. blankii obtained from a cystic fibrosis patient in Brazil [2] . The ITS region of rDNA sequences from C. blankii CBS1898, C. blankii CBS6427 and several other closely related species [6] , as well as sequences from other well-known pathogenic Candida spp.…”
Section: Resultsmentioning
confidence: 95%
See 3 more Smart Citations